Holen Sie sich die Stockscreener-App
2.05
1.44%
-0.03
Handel nachbörslich:
2.04
-0.010
-0.49%
Dare Bioscience Inc Aktie (DARE) Neueste Nachrichten
Daré Bioscience launches prescription-free vaginal probiotic capsule for microbiome support - Contemporary OB/GYN
Dare Bioscience Company Profile & Introduction - Moomoo
Price to earnings forward of Dare Bioscience, Inc. – NASDAQ:DARE - TradingView
Dare Bioscience (DARE) director receives 23,696 RSUs in lieu of cash pay - Stock Titan
Dare Bioscience (DARE) director awarded 30,805 RSUs as board compensation - Stock Titan
Dare Bioscience (DARE) grants 38,862 RSUs to board director - Stock Titan
Dare Bioscience (DARE) director receives 26,540 RSUs in lieu of cash fees - Stock Titan
Daré Bioscience Launches Flora Sync LF5 Vaginal Probiotic, Marks First Direct Consumer Product Revenue - Quiver Quantitative
Daré Bioscience’s vaginal probiotic is now for sale online - Stock Titan
Daré Bioscience, Inc.(NasdaqCM: DARE) added to Russell 3000E Growth Benchmark - marketscreener.com
Daré Bioscience, Inc.(NasdaqCM: DARE) added to Russell 3000E Index - marketscreener.com
Daré Bioscience, Inc.(NasdaqCM: DARE) added to Russell Microcap Index - marketscreener.com
Daré Bioscience, Inc.(NasdaqCM:DARE) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Dare Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5 in Virtual Investor What This Means Segment - marketscreener.com
Dare Bioscience Inc (DARE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dare Bioscience, Inc. Actuals & Estimates (NASDAQ:DARE) - TradingView
DARE Forecast — Price Target — Prediction for 2027 - TradingView
Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor 'What This Means” Segment - The Manila Times
Daré Bioscience Highlights Revenue Opportunity as CEO - GlobeNewswire
Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment - Yahoo! Finance Canada
Daré Bioscience, Inc. (DARE) Presents at BIO International Convention 2026Slideshow (NASDAQ:DARE) 2026-06-23 - Seeking Alpha
Daré Bioscience Issues New Corporate Investor Presentation - TipRanks
Form 8K Dare Bioscience Inc For: 22 June By Investing.com - Investing.com South Africa
Dare Bioscience (DARE) unveils June 22, 2026 corporate investor presentation - Stock Titan
Dare Bioscience Inc (DARE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Daré Bioscience to Present Corporate Strategy and Participate in Multiple Speaking Engagements at BIO International Convention 2026 - Quiver Quantitative
Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026 - GlobeNewswire
Dare Bioscience Inc (DARE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dare Bioscience Inc (DARE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dare Bioscience Inc (DARE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dare Bioscience Inc (DARE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dare Bioscience Inc (DARE) Institutional Confidence - TradingKey
Dare Bioscience Inc (DARE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dare Bioscience Inc (DARE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ovaprene phase 3 interim data supports potential of monthly hormone-free contraceptive - Contemporary OB/GYN
Dare Bioscience (DARE) Holds Near Support After Marginal DeclineSector ETF Flow - newsline.com
Daré Bioscience Shareholders Back Governance and Capital Plans - The Globe and Mail
Daré Bioscience (NASDAQ: DARE) OKs equity line and boosts incentive plan shares - Stock Titan
Dare Bioscience (DARE) director receives 10,000 stock option grant - Stock Titan
Director Susan L. Kelley receives 10,000 Dare Bioscience (DARE) stock options - Stock Titan
Director at Dare Bioscience (NASDAQ: DARE) receives 10,000 stock options grant - Stock Titan
Director Gregory Matz receives 10,000 Dare Bioscience (DARE) stock options - Stock Titan
Dare Bioscience (DARE) director receives 10,000 stock options at $2.03 strike - Stock Titan
Dare Bioscience Inc Annual Shareholders Meeting Transcript - GuruFocus
Daré Bioscience to launch vaginal probiotic product - Investing.com
Daré Bioscience to launch vaginal probiotic product By Investing.com - Investing.com South Africa
Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules - The Manila Times
New vaginal probiotic aims to support comfort — with 30% launch discount - Stock Titan
Why Investors Are Suddenly Paying Attention to One of Healthcare’s Most Overlooked Markets - Barchart.com
DARE Stock Price, Quote & Chart | DARE BIOSCIENCE INC (NASDAQ:DARE) - ChartMill
DAREDare Bioscience Inc Stock Price and Quote - Finviz
Dare Bioscience (DARE) Dips 2.15%, Hovers Above Key Support at $2.17ETF NAV Deviation - newsline.com
Dare Bioscience (DARE) Edges Higher Amid Steady Support LevelsThematic ETF Flow - The Legal Advocate
Daré Bioscience reports interim phase 3 data for Ovaprene By Investing.com - Investing.com Nigeria
Dare Bioscience (DARE) Secures Final $1M Grant from NIH for HPV Treatment - GuruFocus
Daré Bioscience receives second $1M NIH funding tranche - Investing.com UK
Daré Bioscience receives second $1M NIH funding tranche By Investing.com - Investing.com South Africa
1.18%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):